Jasper Therapeutics Inc Cash Flow Conversion Efficiency
Jasper Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Jasper Therapeutics Inc (JSPR) has a cash flow conversion efficiency ratio of -4.897x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.92 Million) by net assets ($1.41 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Jasper Therapeutics Inc (2019–2025)
Cash flow conversion efficiency of Jasper Therapeutics Inc from 2019 to 2025. This chart illustrates how Jasper Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Jasper Therapeutics Inc for real-time trading data and today's change.
Jasper Therapeutics Inc Cash Flow Conversion Ratio Explained
Jasper Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Jasper Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jasper Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Jasper Therapeutics Inc stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Deltamac Taiwan Co Ltd
TWO:6144
|
0.006x |
|
Century Casinos Inc
NASDAQ:CNTY
|
-0.241x |
|
Fuji Finance Indonesia Tbk PT
JK:FUJI
|
0.122x |
|
UMS-Neiken Group Bhd
KLSE:7227
|
-0.009x |
|
Dorsavi Ltd
AU:DVL
|
-0.251x |
|
Shradha Infraprojects Limited
NSE:SHRADHA
|
-0.075x |
|
ATP 30 Public Company Limited
BK:ATP30
|
0.090x |
|
Microba Life Sciences Ltd
AU:MAP
|
-0.184x |
Annual Cash Flow Conversion Efficiency for Jasper Therapeutics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Jasper Therapeutics Inc from 2019 to 2025. Review Jasper Therapeutics Inc leverage flexibility ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $4.15 Million | $-77.16 Million | -18.589x | -1731.30% |
| 2024-12-31 | $61.67 Million | $-62.60 Million | -1.015x | -52.92% |
| 2023-12-31 | $78.44 Million | $-52.07 Million | -0.664x | +47.91% |
| 2022-12-31 | $35.99 Million | $-45.86 Million | -1.274x | -163.02% |
| 2021-12-31 | $69.52 Million | $-33.68 Million | -0.484x | -193.17% |
| 2020-12-31 | $-35.13 Million | $-18.27 Million | 0.520x | +657.27% |
| 2019-12-31 | $21.10 Million | $-1.97 Million | -0.093x | -- |
About Jasper Therapeutics Inc
Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. It is advancing a pipeline of medicines, including KP-104, a dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other unmet need nephrology disorders; Briquili… Read more